{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:01:39Z","timestamp":1791568899219,"version":"4.3.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Integrase inhibitor\u2013based (INSTI) antiretroviral therapy (ART) regimens are preferred for most people with HIV (PWH). We examined factors associated with INSTI use among PWH in San Francisco who started ART in 2009\u20132016. PWH who experienced homelessness were less likely, and older PWH were more likely, to use an INSTI.<\/jats:p>","DOI":"10.1093\/ofid\/ofab139","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T18:04:15Z","timestamp":1616263455000},"source":"Crossref","is-referenced-by-count":7,"title":["Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6368-8664","authenticated-orcid":false,"given":"Matthew A","family":"Spinelli","sequence":"first","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A","family":"Hessol","sequence":"additional","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA"},{"name":"San Francisco Department of Public Health, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra K","family":"Schwarcz","sequence":"additional","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA"},{"name":"San Francisco Department of Public Health, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Scheer","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-1994","authenticated-orcid":false,"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chin Hsu","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"2021070901201388000_CIT0001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021070901201388000_CIT0002","doi-asserted-by":"crossref","DOI":"10.1596\/978-1-4648-0527-1_ch17","article-title":"Pandemics: risks, impacts, and mitigation","volume-title":"Disease Control Priorities: Improving Health and Reducing Poverty.","author":"Madhav","year":"2017","edition":"3rd ed"},{"key":"2021070901201388000_CIT0003","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"2021070901201388000_CIT0004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir Ther"},{"key":"2021070901201388000_CIT0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021070901201388000_CIT0006","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/aje\/kwy191","article-title":"Reassessing the global mortality burden of the 1918 influenza pandemic","volume":"187","author":"Spreeuwenberg","year":"2018","journal-title":"Am J Epidemiol"},{"key":"2021070901201388000_CIT0007","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2242","article-title":"HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study","volume":"169","author":"Nance","year":"2018","journal-title":"Ann Intern Med"},{"key":"2021070901201388000_CIT0008","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofy035","article-title":"Degree of housing instability shows independent \u201cdose-response\u201d with virologic suppression rates among people living with human immunodeficiency virus","volume":"5","author":"Clemenzi-Allen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021070901201388000_CIT0009","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1097\/QAD.0000000000002677","article-title":"Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19","volume":"34","author":"Spinelli","year":"2020","journal-title":"AIDS"},{"key":"2021070901201388000_CIT0010","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/QAD.0000000000002287","article-title":"Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city","volume":"33","author":"Spinelli","year":"2019","journal-title":"AIDS"},{"key":"2021070901201388000_CIT0011","article-title":"San Francisco HIV Epidemiology Annual Report 2019","author":"Enanoria","year":"2020","journal-title":"San Francisco Department of Public Health HIV Epidemiology Section"},{"key":"2021070901201388000_CIT0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/OLQ.0000000000000939","article-title":"Evaluating the impact of housing status on gonorrhea and chlamydia screening in an HIV primary care setting","volume":"46","author":"Clemenzi-Allen","year":"2019","journal-title":"Sex Transm Dis"},{"key":"2021070901201388000_CIT0013","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pec.2011.03.012","article-title":"Factors associated with the accuracy of physicians\u2019 predictions of patient adherence","volume":"85","author":"Phillips","year":"2011","journal-title":"Patient Educ Couns"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab139\/36649027\/ofab139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab139\/38885479\/ofab139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab139\/38885479\/ofab139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T07:41:32Z","timestamp":1625816492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab139\/6179260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab139","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,3,20]]},"article-number":"ofab139"}}